In this study, we presented a combination treatment, that integrated RFA, LTX-315, and anti-CTLA-4 antibody, for more effective management of HCC, and explored the potential mechanisms, with an aim to reduce the tumor recurrence after RFA of malignant solid tumors and improve the long-term survival of these patients. This evidence concerns the gene CTLA4 and cancer.